PTC Therapeutics, Inc.
PTCT
$66.71
$2.223.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 164.68M | 211.01M | 178.88M | 1.18B | 213.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 164.68M | 211.01M | 178.88M | 1.18B | 213.17M |
| Cost of Revenue | 140.08M | 115.94M | 124.41M | 121.84M | 141.05M |
| Gross Profit | 24.60M | 95.07M | 54.47M | 1.05B | 72.12M |
| SG&A Expenses | 96.87M | 84.05M | 85.26M | 80.96M | 84.68M |
| Depreciation & Amortization | 9.35M | 7.53M | 4.06M | 3.80M | 3.31M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 246.30M | 207.52M | 213.73M | 206.59M | 229.04M |
| Operating Income | -81.62M | 3.49M | -34.86M | 969.50M | -15.87M |
| Income Before Tax | -139.08M | -23.07M | -71.05M | 929.83M | -94.70M |
| Income Tax Expenses | -4.12M | -38.97M | -6.20M | 63.27M | -28.81M |
| Earnings from Continuing Operations | -134.97M | 15.90M | -64.85M | 866.56M | -65.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.97M | 15.90M | -64.85M | 866.56M | -65.89M |
| EBIT | -81.62M | 3.49M | -34.86M | 969.50M | -15.87M |
| EBITDA | -68.72M | 14.60M | -27.28M | 976.72M | -9.11M |
| EPS Basic | -1.67 | 0.20 | -0.83 | 11.09 | -0.85 |
| Normalized Basic EPS | -1.16 | -0.25 | -0.57 | 7.45 | 0.36 |
| EPS Diluted | -1.67 | 0.20 | -0.83 | 10.04 | -0.85 |
| Normalized Diluted EPS | -1.16 | -0.23 | -0.57 | 6.74 | 0.36 |
| Average Basic Shares Outstanding | 80.69M | 78.47M | 78.15M | 78.12M | 77.20M |
| Average Diluted Shares Outstanding | 80.69M | 87.12M | 78.15M | 86.39M | 77.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |